Psoriasis
Conditions
Interventions
Control:NA
Psoriasis:Placebo and drug
Parapsoriasis:Placebo and drug
Pityriasis rubra pilaris:Placebo and drug
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Control(1)Health male or female,18-65 year old (2)The subject has completed informed consent; (3) voluntary participation in this study, and to comply with the test requirements, any discomfort can respond in a timely manner; (4) the subject's arm or test site is not severely damaged; (5) the subject can ensure that the test site during the test does not carry out intense scrub or SPA treatment; (6) the subject can accept the test site patch test materials, and instrument testing; (7) there is no pregnancy or lactation program throughout the trial period, also avoid pregnancy; (8) Subjects using hormone replacement therapy or steroidally controlled fertility should be able to ensure that the original habit is maintained during the trial, and that subjects who do not use such hormones should ensure that they are not used during the trial; (9) Subjects who are taking nutritional supplements should maintain their original eating habits during the trial and explain to the research center; (10) nearly a month have not used topical or oral corticosteroids; (11) Subjects are able to receive regular follow-up visits according to the project requirements Patient group: (1) Healthy male or female, 18-65 years of age; (2) the subject has completed informed consent; (3) voluntary participation in this study, and to comply with the test requirements, any discomfort can respond in a timely manner; (4) subjects by clinical evaluation or pathological diagnosis of psoriasis, vice psoriasis or hair red rash; (5) the subject's arm or test site is not seriously damaged; (6) the subject can ensure that the test site during the test does not carry out intense scrub or SPA treatment; (7) Subjects are able to receive the test site and apply the test materials to the instrument. (8) there is no pregnancy or lactation program throughout the trial period, also avoid pregnancy; (9) Subjects that are using hormone replacement therapy or hormone control fertility should be able to ensure that during the trial period Maintain the original habits, no use of such hormones should ensure that the subjects during the trial do not use the hormone; (10) Subjects who are taking nutritional supplements should maintain their original eating habits during the trial and explain to the research center; (11) nearly a month without oral corticosteroid drugs for treatment; (12) Subjects are able to receive regular follow-up visits according to the project requirements;
Exclusion criteria
Exclusion criteria: Control: (1) with skin diseases (atopic dermatoses, psoriasis, eczema, etc.), clinical evaluation that is not suitable for participants in the project; (2) pregnant or lactating or recent family planning of the subject; (3) subjects who were orally administered corticosteroids within the last month; (4) the test site has birthmarks, scratches, white spots, nevi, keloids and other effects of skin tests; (5) subjects who have had a history of acute and chronic skin disease, or who may be affected by physical fitness; (6) subjects who have participated in other clinical studies within the last month; (7) daily working life can not be avoided on the test site of the subjects scrub or soak; Patients Group (1) patients with psoriasis, vice psoriasis or hair red rash are not in the early stages of the disease; (2) pregnant or lactating or recent family planning of the subject; (3) nearly a month of oral corticosteroid treatment of subjects; (4) the test site has birthmarks, scratches, white spots, nevi, keloids and other effects of skin tests; (5) other subjects with a history of acute or chronic skin disease, or who may have a physical condition that may affect the outcome of the trial; (6) subjects who have participated in other clinical studies within the last month; (7) daily working life can not be avoided on the test site of the subjects scrub or soak;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| skin metabolic rate;skin depth;transepidermal water loss rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| skin microcirculation; | — |
Countries
China
Contacts
Public ContactZou Ying
Shanghai Skin Disease Hospital
Outcome results
None listed